{
    "clinical_study": {
        "@rank": "166720", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Compare the safety and efficacy of acellular 2-component vs. acellular\n      multicomponent vs. whole-cell pertussis vaccine vs. placebo in infants living in Sweden.\n\n      II.  Compare the relative protection of each vaccine against atypical or subclinical\n      pertussis infection.\n\n      III.  Analyze possible laboratory correlates to vaccine protection."
        }, 
        "brief_title": "Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines", 
        "condition": "Pertussis", 
        "condition_browse": {
            "mesh_term": "Whooping Cough"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double-blind study.  Patients are stratified by\n      participating institution.\n\n      The first group of infants receives a vaccine composed of inactivated pertussis toxin (iPT)\n      and filamentous hemagglutin (FHA).\n\n      The second group receives a vaccine containing iPT, FHA, pertactin, agglutinogen 2, and\n      agglutinogen 3.\n\n      The third group receives a whole-cell pertussis vaccine. The fourth group receives a\n      diphtheria-tetanus vaccine as the control. All vaccines are given as an intramuscular\n      injection, at 2-3, 4, and 6 months of age.\n\n      Close surveillance of infants and families continues for 2-3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Population Characteristics--\n\n          -  Infants aged 2 months at planned date of first vaccination\n\n          -  No prior pertussis confirmed by culture\n\n          -  The following do not exclude: Down syndrome Prematurity Healthy babies vaccinated\n             according to chronological age Recent pertussis exposure Seizures in parent or\n             sibling Sudden infant death in sibling Close relative with history of anaphylaxis or\n             allergy Close relative with history of strong reaction to vaccination\n\n        --Patient Characteristics--\n\n          -  Age: Under 3 months\n\n          -  Renal: No renal failure\n\n          -  Other: No prior gammaglobulin No requirement for immunosuppressives, e.g., HIV\n             infection No manifest immunosuppression No serious chronic illness associated with\n             failure to thrive No cardiac disease No progressive neurologic disease No\n             uncontrolled epilepsy or infantile spasms No parental language or communication\n             barrier"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "3 Months", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": "10000", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004799", 
            "org_study_id": "199/11953", 
            "secondary_id": "NBL-SS-19910415"
        }, 
        "intervention": [
            {
                "intervention_name": "whole-cell pertussis vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "diphtheria-tetanus vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "keyword": [
            "bacterial infection", 
            "immunologic disorders and infectious disorders", 
            "pertussis", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "National Bacteriological Laboratory", 
            "last_name": "Patrick Olin", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004799"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Bacteriological Laboratory", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 1991", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 1997"
    }, 
    "geocoordinates": {}
}